title: Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model.
abstract: Daily supplementation with the essential trace mineral selenium significantly reduced prostate cancer risk in men in the Nutritional Prevention of Cancer Trial. However, the optimal intake of selenium for prostate cancer prevention is unknown. We hypothesized that selenium significantly regulates the extent of genotoxic damage within the aging prostate and that the relationship between dietary selenium intake and DNA damage is non-linear, i.e. more selenium is not necessarily better. To test this hypothesis, we conducted a randomized feeding trial in which 49 elderly beagle dogs (physiologically equivalent to 62-69-year-old men) received nutritionally adequate or supranutritional levels of selenium for 7 months, in order to mimic the range of dietary selenium intake of men in the United States. Our results demonstrate an intriguing U-shaped dose-response relationship between selenium status (toenail selenium concentration) and the extent of DNA damage (alkaline Comet assay) within the prostate. Further, we demonstrate that the concentration of selenium that minimizes DNA damage in the aging dog prostate remarkably parallels the selenium concentration in men that minimizes prostate cancer risk. By studying elderly dogs, the only non-human animal model of spontaneous prostate cancer, we have established a new approach to bridge the gap between laboratory and human studies that can be used to select the appropriate dose of anticancer agents for large-scale human cancer prevention trials. From the U-shaped dose-response, it follows that not all men will necessarily benefit from increasing their selenium intake and that measurement of baseline nutrient status should be required for all individuals in prevention trials to avoid oversupplementation.
authors.affiliation: Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, IN 47907, USA. dwaters@gpmcf.org
authors.forename: David J
authors.initials: DJ
authors.lastname: Waters
authors.forename: Shuren
authors.initials: S
authors.lastname: Shen
authors.forename: Lawrence T
authors.initials: LT
authors.lastname: Glickman
authors.forename: Dawn M
authors.initials: DM
authors.lastname: Cooley
authors.forename: David G
authors.initials: DG
authors.lastname: Bostwick
authors.forename: Junqi
authors.initials: J
authors.lastname: Qian
authors.forename: Gerald F
authors.initials: GF
authors.lastname: Combs
authors.forename: J Steven
authors.initials: JS
authors.lastname: Morris
mesh_terms: D000367:Age Factors; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology*; D004249:DNA Damage; D019587:Dietary Supplements; D004195:Disease Models, Animal; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000517:prevention & control* / Q000662:veterinary; D011897:Random Allocation; D012643:Selenium / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000975:Antioxidants; D012643:Selenium